论文部分内容阅读
本文报告1983～1990年采用含SHRZ方案治疗351例初治肺结核,观察其对肝功影响。结果:治疗中出现胃肠道反应12例(3.4％);肝功异常18例(5.1％);治疗前有肝炎病史者18例,于治疗后肝功异常5例(27.8％);治疗前HBsAg阳性23例,于治疗后肝功异常3例(13.0%),停药l一2周肝功恢复继用原方案无不良反应。6例(l .7%)因多项异常,症状明显而改变方案。全部病例无1例黄疽发生或死亡。故在选用方案前要详询用药史及肝病史,或并用肝太乐、维
This article reports from 1983 to 1990 using SHRZ program containing 351 cases of untreated tuberculosis, observed its impact on liver function. Results: There were 12 cases (3.4%) of gastrointestinal reactions in treatment, 18 cases (5.1%) of abnormal liver function, 18 cases of hepatitis before treatment, 5 cases (27.8%) of liver abnormalities after treatment, HBsAg positive in 23 cases, 3 cases of abnormal liver function after treatment (13.0%), l-2 weeks of withdrawal of liver function recovery after the original program without adverse reactions. Six cases (1.7%) due to a number of abnormalities, symptoms and change the program. No case of jaundice occurred or died in all cases. Therefore, in the choice of program before going to the drug history and history of liver disease, or with liver too Lok, Victoria